Novartis AG NOVN

SWX: NOVN | ISIN: CH0012005267 22/10/2025

104,86 CHF (+0,29%)

(+0,29%) 22/10/2025

Grafiek Novartis AG

Grafiek Novartis AG

1 dag1d 0,29%
1 week1w 0,50%
1 maand1m 7,53%
3 maanden3m 12,61%
6 maanden6m 15,36%
1 jaar1j 6,26%
5 jaar5j 37,11%

dinsdag 28 oktober 2025, 06:00

Kwartaalcijfers (3de kwartaal)

Novartis AG in het nieuws

Toon enkel gratis nieuws

22 oktober 2025 · Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR) · Persbericht

22 oktober 2025 · Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer · Persbericht

19 oktober 2025 · PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer · Persbericht

17 oktober 2025 · Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population · Persbericht

17 oktober 2025 · Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML · Persbericht

16 oktober 2025 · Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN) · Persbericht

30 september 2025 · Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) · Persbericht

30 september 2025 · Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) · Persbericht

29 september 2025 · Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US · Persbericht

29 september 2025 · Novartis announces commencement of tender offer to acquire Tourmaline Bio · Persbericht

Profiel Novartis AG

Gezondheidstechnologie

Medicinale en botanische productie

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe